替奈普酶与阿替普酶治疗急性缺血性卒中患者:ORIGINAL随机临床试验
ORIGINAL研究是在中国55家神经内科诊所和卒中中心开展的多中心、活性对照、平行组、随机、开放标签、盲法终点、非劣效性试验,纳入症状发作4.5小时内的急性缺血性卒中患者1489例,比较静脉替奈普酶0.25 mg/kg与阿替普酶0.9 mg/kg。结果显示替奈普酶在90天mRS 0或1分比例上非劣效于阿替普酶,安全性特征相似。
要点
- 替奈普酶0.25 mg/kg在90天良好功能结局上非劣效于阿替普酶0.9 mg/kg。
- 两组症状性颅内出血发生率均为1.2%,90天全因死亡率相似。
- 作者认为替奈普酶可作为阿替普酶的合适替代方案。
核心结论
- 在症状发作4.5小时内适合静脉溶栓的急性缺血性卒中患者中,替奈普酶在90天良好功能结局(mRS评分0或1分)方面非劣效于阿替普酶,且安全性特征相似。
- 作者认为本研究结果支持替奈普酶作为该情境下阿替普酶的合适替代方案。
研究设计与样本
- ORIGINAL研究是一项多中心、活性对照、平行组、随机、开放标签、盲法终点、非劣效性试验,于2021年7月14日至2023年7月14日开展。
- 研究从中国55家神经内科诊所和卒中中心招募患者,纳入标准为急性缺血性卒中、美国国立卫生研究院卒中量表评分1至25分且存在可测量的神经功能缺损、症状持续至少30分钟无显著改善。
- 患者按1:1随机分配,在症状发作4.5小时内接受静脉替奈普酶0.25 mg/kg或静脉阿替普酶0.9 mg/kg。
- 共随机分配1489例患者,全分析集纳入1465例(替奈普酶组732例,阿替普酶组733例),446例(30.4%)为女性。
主要发现
- 主要结局(90天mRS评分0或1分)在替奈普酶组发生率为72.7%(532/732),阿替普酶组为70.3%(515/733),风险比(RR)为1.03(95%CI 0.97-1.09),达到非劣效性阈值(RR界值0.937)。
- 症状性颅内出血(按欧洲急性卒中协作研究III定义)在替奈普酶组发生9例(1.2%),阿替普酶组发生9例(1.2%),RR为1.01(95%CI 0.37-2.70)。
- 90天全因死亡率在替奈普酶组为4.6%(34/732),阿替普酶组为5.8%(43/736),RR为0.80(95%CI 0.51-1.23)。
关键数值与推荐
- 主要结局非劣效性检验采用RR界值0.937。
- 症状性颅内出血采用欧洲急性卒中协作研究III定义。
- 主要结局为90天mRS评分0或1分(无症状或无明显残疾)的患者比例。
临床怎么用
- 作者认为,在症状发作4.5小时内适合静脉溶栓的急性缺血性卒中患者中,替奈普酶可作为阿替普酶的合适替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tenecteplase is a bioengineered variant of alteplase with greater fibrin specificity and a longer half-life, allowing single-bolus administration. Evidence on the treatment effect of tenecteplase 0.25 mg/kg in Chinese patients with acute ischemic stroke (AIS) is limited. OBJECTIVE: To establish the noninferiority of tenecteplase to alteplase in patients with AIS within 4.5 hours of symptom onset. DESIGN, SETTING, AND PARTICIPANTS: The ORIGINAL study was a multicenter, active-controlled, parallel-group, randomized, open-label, blinded end point, noninferiority trial conducted between July 14, 2021, and July 14, 2023. Participants were recruited from 55 neurology clinics and stroke centers in China and were eligible if they had AIS with a National Institutes of Health Stroke Scale score of 1 to 25 with measurable neurologic deficit and were symptomatic for at least 30 minutes without significant improvement. INTERVENTIONS: Patients were randomized (1:1) within 4.5 hours of symptom onset to receive intravenous tenecteplase (0.25 mg/kg) or intravenous alteplase (0.9 mg/kg). MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients with a modified Rankin Scale (mRS) score of 0 or 1 (no symptoms or no significant disability) at day 90, tested for noninferiority (risk ratio [RR] margin, 0.937). Safety end points included symptomatic intracerebral hemorrhage (per European Cooperative Acute Stroke Study III definition) and 90-day all-cause mortality. RESULTS: Among the 1489 patients randomized, 1465 patients were included in the full analysis set (732 in the tenecteplase group; 733 in the alteplase group) and 446 (30.4%) were female. The primary outcome occurred in 72.7% (532/732) of patients receiving tenecteplase and 70.3% (515/733) receiving alteplase (RR, 1.03 [95% CI, 0.97-1.09]; noninferiority threshold met). Symptomatic intracerebral hemorrhage occurred in 9 patients (1.2%) in each group (RR, 1.01 [95% CI, 0.37-2.70]). The 90-day mortality rate was 4.6% (34/732) in the tenecteplase group and 5.8% (43/736) in the alteplase group (RR, 0.80 [95% CI, 0.51-1.23]). CONCLUSIONS AND RELEVANCE: In patients with AIS eligible for intravenous thrombolysis within 4.5 hours after stroke onset, tenecteplase was noninferior to alteplase with respect to excellent functional outcome (mRS score of 0 or 1) at 90 days and had a similar safety profile. Findings from this study support tenecteplase as a suitable alternative to alteplase in this setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04915729.
引用
- Meng X, Li S, Dai H, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial. JAMA. 2024. PMID: 39264623. doi:10.1001/jama.2024.14721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。